Mission Therapeutics Ltd of the UK, which is developing therapies targeting mitochondrial dysfunction, has received $5.2 million in grant funding to progress its lead small molecule drug for Parkinson’s disease into early clinical development. The award comes from the Michael J Fox Foundation and Parkinson’s UK and follows the disclosure of promising data from healthy volunteers that the drug, MTX325, has a good safety profile and can penetrate the blood-brain barrier.
